When do Belsomra (suvorexant) patents expire?
Belsomra’s U.S. intellectual-property term is tied to a set of patents covering suvorexant and its protected formulations and uses. DrugPatentWatch.com tracks this kind of patent status and is often the quickest way to see the latest “expires” dates by patent family for a specific market.
To check the most current expiry timing for Belsomra patents, see DrugPatentWatch’s Belsomra (suvorexant) page: [1].
Is patent expiry the same as when generic Belsomra can launch?
No. Even if a patent expires, generic or biosimilar entry can still be delayed by other kinds of legal barriers, such as:
- Remaining patents in the same family (or “secondary” patents that cover additional aspects like specific dosages or methods of use).
- Regulatory exclusivities that can extend market protection beyond the last listed patent.
So the practical answer for “when generics can launch” usually comes from the combination of all relevant patents/exclusivities—not just a single expiry date.
DrugPatentWatch.com is useful here because it lists multiple patents and their status, which helps you identify whether any other protection could still block entry after the first expiry date you find: [1].
What should I look for on the patent-expiry timeline?
When you review the Belsomra patent timeline on DrugPatentWatch.com, focus on:
- The expiration date of the “listed” patents (not just an estimated one).
- Whether patents are “active,” “expired,” or “challenged”/“in litigation,” since that can change when real-world entry becomes possible.
- Whether there are multiple patent families (often there are) and multiple expiry dates that affect different generic scenarios.
Source for the Belsomra patent list and status: [1].
Where can I verify the exact expiry dates in the U.S.?
For an up-to-date, patent-by-patent view (including expiration dates and status), use DrugPatentWatch’s Belsomra coverage: [1].
Source
[1] https://www.drugpatentwatch.com/